Beyond gout: uric acid and cardiovascular diseases

Area of Science:

• Cardiology
• Nephrology
• Rheumatology

Background:

• Hyperuricemia, characterized by elevated uric acid levels, is increasingly recognized as a significant risk factor for cardiovascular (CV) disease.
• Gout, a condition resulting from hyperuricemia, shares a complex relationship with CV complications.

Purpose of the Study:

• To review clinical and experimental evidence linking hyperuricemia and gout to cardiovascular outcomes.
• To evaluate the potential of xantine-oxidase (XO) inhibitors in managing CV risks associated with high uric acid levels.

Main Methods:

• A comprehensive literature search was conducted using PubMed to identify relevant clinical and experimental studies.
• Articles were selected based on their direct relevance to the association between hyperuricemia, gout, and cardiovascular disease.

Main Results:

• Evidence suggests a potential causal association between hyperuricemia and adverse CV outcomes.
• Studies indicate that XO inhibitors improve endothelial function, reduce oxidative stress, and enhance cardiac function.
• Improvements in hemodynamics and inflammatory markers were observed in patients treated with XO inhibitors.

Conclusions:

• Xantine-oxidase inhibitors represent a promising therapeutic strategy for mitigating CV consequences of hyperuricemia.
• While allopurinol and febuxostat show potential, further large-scale studies are necessary to establish definitive clinical recommendations for asymptomatic individuals with high CV risk.